Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw unusually-strong trading volume on Monday . Approximately 2,862,552 shares changed hands during mid-day trading, an increase of 151% from the previous session’s volume of 1,140,443 shares.The stock last traded at $0.62 and had previously closed at $0.59.
Several equities research analysts have recently commented on NBY shares. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, November 20th. LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 price target for the company.
The firm’s fifty day moving average price is $0.68 and its 200 day moving average price is $1.02.
About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Further Reading: Hang Seng Index (HSI)
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.